Press Releases

BIOMS MEDICAL TO PRESENT AT THE SACHS ASSOCIATES 5TH ANNUAL NORTH AMERICA FORUM

Edmonton, Alberta, March 10, 2006 – BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President Corporate Affairs, will give a corporate presentation at The Sachs Associates 5th Annual North America Forum in Boston.

WHEN: Monday March 13th, 2006 at 12:55pm (EST)

WHERE: The Fairmont Copley Plaza, Boston

About Sachs Associates North America Forum
This leading international forum is an excellent platform for emerging growth and established biotech companies from the US and overseas to address investors, their advisers and media. Every year around 60 are selected to present, with listed companies presenting on the first day. Workshop sectors cover Therapeutics, Immunology/Oncology, Post Genomics and Cardiovascular. For more information visit http://www.sachsforum.com/boston06.html

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.